SCHEMBL3977181

SCHEMBL3977181

Cc1ccc(C)c(-n2nc(Cc3ccccc3)cc2Nc2ncccc2C(=O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
GAA P10253 1/20 0.48
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
MAPT P10636 2/20 0.47
DHODH Q02127 8/20 0.43
CLCN2 P51788 1/20 0.43
HTT P42858 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GLA P06280 1/20 0.40
HPGD P15428 1/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.39
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3976262 0.87 LMNA (0.49) LMNAGAAMEN1KMT2ARAB9A
SCHEMBL3859778 0.84 LMNA (0.50) LMNAGAAMEN1KMT2ARAB9A
SCHEMBL3979286 0.83 LMNA (0.51) LMNAGAAMEN1KMT2ARAB9A
SCHEMBL3861464 0.79 DHODH (0.48) LMNAGAAMEN1KMT2ARAB9A
SCHEMBL3974223 0.78 MEN1 (0.49) LMNAGAAMEN1KMT2ARAB9A
SCHEMBL3974751 0.77 KCNJ6 (0.47) LMNAGAAMEN1KMT2ARAB9A
SCHEMBL3974469 0.76 MAPK14 (0.46) LMNAMEN1KMT2ARAB9ANPC1
SCHEMBL3974247 0.75 RAB9A (0.52) LMNARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL3864506 0.75 MAPK14 (0.48) LMNAGAAMEN1KMT2ARAB9A
SCHEMBL3974462 0.75 DHODH (0.48) LMNAGAAMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP LMNA 3423/4885GAA 369/4885MEN1 3766/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP LMNA 3423/4885GAA 369/4885MEN1 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.